Previous 10 | Next 10 |
Baudax Bio ( BXRX ) has slipped under my radar despite receiving shares after its spin-out from Recro Pharma ( REPH ) at the end of 2019. BXRX started trading back in November and is already preparing for a PDUFA for its lead product candidate Anjeso. I quickly scrambled to gather all the fu...
Original Post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...
Investing in companies with superior growth can lead to outstanding returns over the long term. However, picking the best growth stocks is easier said than done, and a good idea without the right implementation can do more harm than good. This is especially true among growth stocks because the...
The healthcare sector seems to be waking up over the past several weeks. Political uncertainty has been hurting healthcare stocks throughout the past year, but this uncertainty seems to be dissipating as the Presidential election approaches, which is being a major tailwind for the healthcare ...
Gainers: EyeGate Pharmaceuticals (NASDAQ: EYEG ) +43% . More news on: EyeGate Pharmaceuticals, Inc., Stage Stores, Inc., Cancer Genetics, Inc., Stocks on the move, Read more ...
Recro Capitalizing on Strong and Growing CDMO Business Business Poised to Continue Driving Revenue and Begin Generating Profits Recro Will Continue to Trade on NASDAQ Under Ticker Symbol “ REPH ” MALVERN, Pa., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, In...
Company Launches with $19 Million in Funding and Rights to IV Meloxicam, Along with Other Clinical-Stage Pipeline Assets Trading of “ BXRX ” Begins Tomorrow on NASDAQ MALVERN, Pa., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) today announced ...
Separation of Baudax Bio as Independent Company Expected to be Completed With Distribution on November 21, 2019 Baudax Bio Common Stock Approved for Listing on the NASDAQ Capital Market MALVERN, Pa., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a phar...
Recro Pharma, Inc. (REPH) Q3 2019 Earnings Conference Call November 08, 2019, 08:00 AM ET Company Participants Claudia Styslinger - IR Gerri Henwood - President & CEO Ryan Lake - CFO Conference Call Participants David Amsellem - Piper Jaffray Esther Hong - Janney Mont...
Recro Pharma (NASDAQ: REPH ): Q3 GAAP EPS of -$0.19 misses by $0.03 . More news on: Recro Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging CoreRx to Commence a Tender Offer for all Outstanding Shares of Societal CDMO, Inc. CLEARWATE...
Agreement Broadly Applicable to All Therapeutic Areas with Specific Focus on the Growing Psychedelic and Cannabinoid Drug Development Markets Complementary Capabilities Range from API Manufacturing through Process Development and cGMP Manufacturing to Fill/Finish GAINESVILLE, Ga. ...
Recorded Q3 Revenue of $23.6 Million Signed Multiple New Business Agreements with New and Existing Customers Closed Public Offering Raising Gross Proceeds of Approximately $8.3 Million Initiated Corporate Restructuring; Expected to Result in Annualized Savings of Approxi...